Document is current
Any future updates will be listed below
-
Authors
Rose, Tracy L.
Chism, David D.
Alva, Ajjai S.
Deal, Allison M.
Maygarden, Susan J.
Whang, Young E.
Kardos, Jordan
Drier, Anthony
Basch, Ethan
Godley, Paul A.
Dunn, Mary W.
Kim, William Y.
Milowsky, Matthew I.
- License Information
-
More Information
Article History
Received: 27 March 2018
Revised: 9 July 2018
Accepted: 19 July 2018
First Online: 8 October 2018
Competing interests
: W.Y.K. has research funding from GeneCentric and IBM. D.D.C. has a scientific advisory role for Karyopharm Inc. and Exelixis. Y.E.W. has research funding from Astellas Pharma, Innocrin Pharmaceuticals, Inovio Pharmaceuticals, and Tokai Pharmaceuticals. M.I.M. receives research funding from Merck, BMS, and Genentech. The other authors declare no competing interests.
: The protocol and all amendments were reviewed by the Institutional Review Board for each study site, and the study was conducted in accordance with the ethical principles of the Declaration of Helsinki and registered with the National Cancer Institute (NCT02334527).
: The clinical data generated during and/or analysed during the current study are available at ExternalRef removed. Other datasets generated during and/or analysed during the current study are available in this article or from the corresponding author upon reasonable request.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
